vs
Embecta Corp.（EMBC）与WSFS FINANCIAL CORP（WSFS）财务数据对比。点击上方公司名可切换其他公司
WSFS FINANCIAL CORP的季度营收约是Embecta Corp.的1.1倍（$275.3M vs $261.2M），WSFS FINANCIAL CORP净利率更高（31.5% vs 16.9%，领先14.6%），WSFS FINANCIAL CORP同比增速更快（7.5% vs -0.3%），过去两年WSFS FINANCIAL CORP的营收复合增速更高（1.7% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
WSFS金融集团是一家金融服务企业，核心子公司WSFS银行是总部位于特拉华州及大特拉华谷地区规模最大、经营历史最久的本地管理银行与财富管理机构。集团共运营115个网点，其中88个为银行网点，分布在宾夕法尼亚、特拉华、新泽西、佛罗里达、弗吉尼亚、内华达六州，提供全面金融服务。
EMBC vs WSFS — 直观对比
营收规模更大
WSFS
是对方的1.1倍
$261.2M
营收增速更快
WSFS
高出7.8%
-0.3%
净利率更高
WSFS
高出14.6%
16.9%
两年增速更快
WSFS
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $275.3M |
| 净利润 | $44.1M | $86.8M |
| 毛利率 | 61.9% | — |
| 营业利润率 | 31.9% | — |
| 净利率 | 16.9% | 31.5% |
| 营收同比 | -0.3% | 7.5% |
| 净利润同比 | — | 31.7% |
| 每股收益（稀释后） | $0.74 | $1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCWSFS
| Q1 26 | — | $275.3M | ||
| Q4 25 | $261.2M | $271.9M | ||
| Q3 25 | $264.0M | $270.5M | ||
| Q2 25 | $295.5M | $267.5M | ||
| Q1 25 | $259.0M | $256.1M | ||
| Q4 24 | $261.9M | $261.5M | ||
| Q3 24 | $286.1M | $267.7M | ||
| Q2 24 | $272.5M | $266.0M |
净利润EMBCWSFS
| Q1 26 | — | $86.8M | ||
| Q4 25 | $44.1M | $72.7M | ||
| Q3 25 | $26.4M | $76.4M | ||
| Q2 25 | $45.5M | $72.3M | ||
| Q1 25 | $23.5M | $65.9M | ||
| Q4 24 | $0 | $64.2M | ||
| Q3 24 | $14.6M | $64.4M | ||
| Q2 24 | $14.7M | $69.3M |
毛利率EMBCWSFS
| Q1 26 | — | — | ||
| Q4 25 | 61.9% | — | ||
| Q3 25 | 60.0% | — | ||
| Q2 25 | 66.7% | — | ||
| Q1 25 | 63.4% | — | ||
| Q4 24 | 60.0% | — | ||
| Q3 24 | 60.7% | — | ||
| Q2 24 | 69.8% | — |
营业利润率EMBCWSFS
| Q1 26 | — | — | ||
| Q4 25 | 31.9% | 35.8% | ||
| Q3 25 | 21.4% | 37.3% | ||
| Q2 25 | 31.8% | 35.7% | ||
| Q1 25 | 24.3% | 34.0% | ||
| Q4 24 | 11.0% | 32.3% | ||
| Q3 24 | 9.2% | 31.9% | ||
| Q2 24 | 20.5% | 34.0% |
净利率EMBCWSFS
| Q1 26 | — | 31.5% | ||
| Q4 25 | 16.9% | 26.7% | ||
| Q3 25 | 10.0% | 28.3% | ||
| Q2 25 | 15.4% | 27.0% | ||
| Q1 25 | 9.1% | 25.7% | ||
| Q4 24 | — | 24.6% | ||
| Q3 24 | 5.1% | 24.1% | ||
| Q2 24 | 5.4% | 26.0% |
每股收益（稀释后）EMBCWSFS
| Q1 26 | — | $1.64 | ||
| Q4 25 | $0.74 | $1.33 | ||
| Q3 25 | $0.44 | $1.37 | ||
| Q2 25 | $0.78 | $1.27 | ||
| Q1 25 | $0.40 | $1.12 | ||
| Q4 24 | $0.00 | $1.08 | ||
| Q3 24 | $0.24 | $1.08 | ||
| Q2 24 | $0.25 | $1.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-613.1M | $2.7B |
| 总资产 | $1.1B | $22.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EMBCWSFS
| Q1 26 | — | — | ||
| Q4 25 | $201.3M | $1.7B | ||
| Q3 25 | $225.5M | — | ||
| Q2 25 | $230.6M | — | ||
| Q1 25 | $209.3M | — | ||
| Q4 24 | $210.0M | $1.2B | ||
| Q3 24 | $267.5M | — | ||
| Q2 24 | $275.1M | — |
总债务EMBCWSFS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | — | — |
股东权益EMBCWSFS
| Q1 26 | — | $2.7B | ||
| Q4 25 | $-613.1M | $2.7B | ||
| Q3 25 | $-650.6M | $2.8B | ||
| Q2 25 | $-669.6M | $2.7B | ||
| Q1 25 | $-736.2M | $2.7B | ||
| Q4 24 | $-768.8M | $2.6B | ||
| Q3 24 | $-738.3M | $2.7B | ||
| Q2 24 | $-763.7M | $2.5B |
总资产EMBCWSFS
| Q1 26 | — | $22.1B | ||
| Q4 25 | $1.1B | $21.3B | ||
| Q3 25 | $1.1B | $20.8B | ||
| Q2 25 | $1.2B | $20.8B | ||
| Q1 25 | $1.1B | $20.5B | ||
| Q4 24 | $1.1B | $20.8B | ||
| Q3 24 | $1.3B | $20.9B | ||
| Q2 24 | $1.3B | $20.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | — |
| 自由现金流经营现金流 - 资本支出 | $16.6M | — |
| 自由现金流率自由现金流/营收 | 6.4% | — |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | 0.39× | — |
| 过去12个月自由现金流最近4个季度 | $205.8M | — |
8季度趋势，按日历期对齐
经营现金流EMBCWSFS
| Q1 26 | — | — | ||
| Q4 25 | $17.2M | $220.0M | ||
| Q3 25 | $84.0M | $121.5M | ||
| Q2 25 | $81.2M | $37.2M | ||
| Q1 25 | $31.8M | $8.7M | ||
| Q4 24 | $-5.3M | $219.9M | ||
| Q3 24 | $26.6M | $3.1M | ||
| Q2 24 | $-2.1M | $44.8M |
自由现金流EMBCWSFS
| Q1 26 | — | — | ||
| Q4 25 | $16.6M | $213.6M | ||
| Q3 25 | $76.7M | $120.3M | ||
| Q2 25 | $80.8M | $35.2M | ||
| Q1 25 | $31.7M | $6.3M | ||
| Q4 24 | $-6.8M | $205.6M | ||
| Q3 24 | — | $-489.0K | ||
| Q2 24 | $-11.8M | $42.1M |
自由现金流率EMBCWSFS
| Q1 26 | — | — | ||
| Q4 25 | 6.4% | 78.6% | ||
| Q3 25 | 29.1% | 44.5% | ||
| Q2 25 | 27.3% | 13.2% | ||
| Q1 25 | 12.2% | 2.5% | ||
| Q4 24 | -2.6% | 78.6% | ||
| Q3 24 | — | -0.2% | ||
| Q2 24 | -4.3% | 15.8% |
资本支出强度EMBCWSFS
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 2.3% | ||
| Q3 25 | 2.8% | 0.5% | ||
| Q2 25 | 0.1% | 0.7% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | 0.6% | 5.5% | ||
| Q3 24 | 0.0% | 1.4% | ||
| Q2 24 | 3.6% | 1.0% |
现金转化率EMBCWSFS
| Q1 26 | — | — | ||
| Q4 25 | 0.39× | 3.03× | ||
| Q3 25 | 3.18× | 1.59× | ||
| Q2 25 | 1.78× | 0.51× | ||
| Q1 25 | 1.35× | 0.13× | ||
| Q4 24 | — | 3.43× | ||
| Q3 24 | 1.82× | 0.05× | ||
| Q2 24 | -0.14× | 0.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
WSFS
暂无分部数据
